ACCEL Lite: AHA Late-Breaker: DCP – Chlorthalidone Compared to Hydrochlorothiazide for the Prevention of CV Events in Patients with HTN
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research - Een podcast door American College of Cardiology - Dinsdagen
Categorieën:
Thiazides are recommended first line agents for the treatment of hypertension. They have been demonstrated to lower cardiovascular disease. Which thiazide to choose has been a long-standing issue. In this interview, Areef Ishani MD, MS and W. Douglas Weaver MD, MACC discuss AHA Late-Breaker: DCP – Chlorthalidone Compared to Hydrochlorothiazide for the Prevention of Cardiovascular Events in Patients with Hypertension. Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
